Đang chuẩn bị liên kết để tải về tài liệu:
Pancreatic adenocarcinoma: Insights into patterns of recurrence and disease behavior

Không đóng trình duyệt đến khi xuất hiện nút TẢI XUỐNG

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers with high metastatic potential. Clinical observations suggest that there is disease heterogeneity among patients with different sites of distant metastases, yielding distinct clinical outcomes. | Pancreatic adenocarcinoma Insights into patterns of recurrence and disease behavior

TÀI LIỆU LIÊN QUAN

Pancreatic cancer stem cells may define tumor stroma characteristics and recurrence patterns in pancreatic ductal adenocarcinoma

A novel feedback loop between high MALAT-1 and low miR-200c-3p promotes cell migration and invasion in pancreatic ductal adenocarcinoma and is predictive of poor prognosis

Outcomes of patients with initially locally advanced pancreatic adenocarcinoma who did not benefit from resection: A prospective cohort study

Proposal for a definition of "Oligometastatic disease in pancreatic cancer"

Histone profiling reveals the H1.3 histone variant as a prognostic biomarker for pancreatic ductal adenocarcinoma

Expression of estrogen receptor beta correlates with adverse prognosis in resected pancreatic adenocarcinoma

Calcium-activated chloride channel regulator 1 as a prognostic biomarker in pancreatic ductal adenocarcinoma

NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): From clinical trials to clinical practice

Macrophage inhibitory cytokine 1 (MIC-1/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma

GLUT-1 as a predictor of worse prognosis in pancreatic adenocarcinoma: Immunohistochemistry study showing the correlation between expression and survival
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.